Home > Pulmonology > ERS 2022 > COPD medication not effective in symptomatic smokers with preserved spirometry

COPD medication not effective in symptomatic smokers with preserved spirometry

Presented By
Prof. MeiLan Han , University of Michigan, MI, USA
Conference
ERS 2022
Trial
Phase 3, RETHINC
Long-acting bronchodilators do not appear to improve respiratory symptoms in symptomatic tobacco-exposed individuals, data from the Rethinc trial indicate. These results suggest that the widespread use of COPD medications in these individuals should be reconsidered. “Current and former smokers with spirometric values within the normal range are frequently treated with bronchodilators or inhaled corticosteroids (ICS),” explained Prof. MeiLan Han (University of Michigan, MI, USA) [1–3]. These individuals are however not included in current GOLD guideline recommendations and a benefit of these medications is not established. The multicentre, randomised, phase 3 RETHINC study (NCT02867761) compared a 12-week treatment of inhaled indacaterol/glycopyrrolate with placebo in current and former smokers with preserved spirometry and respiratory symptoms (n=535) [1]. ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on